EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

2022/11/10 by Josef S Smolen, Robert Landewé, Robert B M Landewé +63 · 42 citations
Medicine · Immunology and Microbiology · #Rheumatoid Arthritis Research and Therapies #Biosimilars and Bioanalytical Methods #Hemophilia Treatment and Research

paper · doi:10.1136/ard-2022-223356

Citations

• 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Cited by

• 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
• Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis
• Impfungen bei Immunsuppression, Immundefekten und immunmodulierenden Therapien: Empfehlungen – Update 2026
• ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)
• Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement
• Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
• Methotrexate continuation increases fracture risk in patients who sustained lower limb insufficiency fractures
• Biomimetically engineered plant-derived exosomes-like nanovesicles for rheumatoid arthritis therapy
• Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
• HandScan criteria versus ACR/EULAR Boolean remission as treatment target in early rheumatoid arthritis: results of a randomized controlled trial
• Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study
• Common genetic variants do not impact clinical prediction of methotrexate treatment outcomes in early rheumatoid arthritis
• Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDs
• Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis
• Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement
• Management and treatment of early rheumatoid arthritis, process and barriers among rheumatologists in Spain: a Delphi consensus
• Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
• Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. [europepmc]
• Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications. [europepmc]
• Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. [europepmc]
• Protein kinases: drug targets for immunological disorders. [europepmc]
• What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. [europepmc]
• Immune-related adverse events of immune checkpoint inhibitors: a review. [europepmc]
• Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. [europepmc]
• A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. [europepmc]
• Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. [europepmc]
• Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). [europepmc]
• Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. [europepmc]
• Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. [europepmc]
• Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. [europepmc]
• The Role of Marine n-3 Polyunsaturated Fatty Acids in Inflammatory-Based Disease: The Case of Rheumatoid Arthritis. [europepmc]
• Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remission. [europepmc]
• EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. [europepmc]
• Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. [europepmc]
• Graphene oxide quantum dots-loaded sinomenine hydrochloride nanocomplexes for effective treatment of rheumatoid arthritis via inducing macrophage repolarization and arresting abnormal proliferation of fibroblast-like synoviocytes. [europepmc]
• Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. [europepmc]
• Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn? [europepmc]
• Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal? [europepmc]
• Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. [europepmc]
• Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies. [europepmc]
• Update on tocilizumab in rheumatoid arthritis: a narrative review. [europepmc]
• Neutrophils in Tissue Injury and Repair: Molecular Mechanisms and Therapeutic Targets. [europepmc]